Dr. Maki is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
160 East 53rd Street
New York, NY 10022
Summary
- I am a medical oncologist with principal clinical specialization in sarcomas of soft tissue and bone, such as osteogenic sarcoma, Ewing sarcoma, GIST, leiomyosarcoma, angiosarcoma, synovial sarcoma and malignant peripheral nerve sheath tumor and other connective tissue tumors such as desmoid tumors and giant cell tumors. I participate in both the experimental therapeutic (phase 1) and sarcoma research programs, and also take part in sarcoma translational research. Offers to collaborate are always welcome.
Please see asco.org to obtain my email address. I do not check this site often. Please also see https://orcid.org/0000-0002-9853-2528 on ORCID for publications.
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1995 - 1998
- Brigham and Women's HospitalResidency, Internal Medicine, 1992 - 1995
- Weill Cornell MedicineClass of 1992
Certifications & Licensure
- CT State Medical License 2023 - 2025
- NJ State Medical License 2020 - 2025
- NY State Medical License 1999 - 2025
- FL State Medical License 2020 - 2024
- PA State Medical License 2019 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- FASCO (Fellow of the American Society of Clinical Oncology) American Society of Clinical Oncology, 2018
- America's Worst Doctors Journal of Irreproducible Results, 2018
- Fellow (FACP) American College of Physicians
Publications & Presentations
PubMed
- 125 citationsOpportunities for improving the therapeutic ratio for patients with sarcomaJay S. Wunder, Torsten O. Nielsen, Robert G. Maki, Brian O'Sullivan, Benjamin A. Alman
The Lancet. Oncology. 2007-06-01 - 518 citationsEribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trialPatrick Schöffski, Sant P. Chawla, Robert G. Maki, Antoine Italiano, Hans Gelderblom
Lancet. 2016-04-16 - 664 citationsComprehensive and Integrated Genomic Characterization of Adult Soft Tissue SarcomasAdam Abeshouse, Clement Adebamowo, Sally N. Adebamowo, Rehan Akbani, Teniola Akeredolu
Cell. 2017-11-02
Journal Articles
- TERT Promoter Mutations in Solitary Fibrous TumorRobert Maki, MD, Histopathology
Press Mentions
- Journal of Clinical Oncology (JCO) PodcastSeptember 30th, 2024
- SHR-A1811 Showed Promise Among Patients with HER2-Expressing Solid TumorsJuly 25th, 2024
- What Is Cardiac Angiosarcoma?November 29th, 2021
- Join now to see all
Professional Memberships
- Member
- Member
- Member
- GEIS: Spanish Sarcoma GroupMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: